Nebulization of nanoparticulate amorphous or crystalline tacrolimus - Single-dose pharmacokinetics study in mice

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 69, Issue 3, 2008, Pages 1057-1066

  Sinswat, Prapasri ^a   Overhoff, Kirk A ^a   McConville, Jason T ^a   Johnston, Keith P ^b   Williams III, Robert O ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b The University of Texas at Austin   (United States)

Author keywords

Amorphous; Crystalline; Nanoparticles; Pulmonary delivery; Tacrolimus (TAC); Ultra rapid freezing (URF)

Indexed keywords

NANOPARTICLE; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; LUNG TRANSPLANTATION; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NEBULIZATION; NONHUMAN; PARTICLE SIZE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY DIFFRACTION;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; AREA UNDER CURVE; CHEMISTRY, PHYSICAL; CRYSTALLIZATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HALF-LIFE; IMMUNOSUPPRESSIVE AGENTS; LUNG; MALE; MICE; MICE, INBRED ICR; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; SOLUTIONS; SURFACE PROPERTIES; TACROLIMUS; X-RAY DIFFRACTION;

EID: 48149100601     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.01.037     Document Type: Article

References (41)

1. Hooks M.A. Tacrolimus, a new immunosuppressant - a review of the literature. Ann. Pharmacother. 28 (1994) 501-511
2. Waldrep J.C. New aerosol drug delivery systems for the treatment of immune-mediated pulmonary diseases. Drugs Today 34 (1998) 549-561
3. Loser K., Balkow S., Higuchi T., Apelt J., Kuhn A., Luger T.A., and Beissert S. FK506 controls CD40L-induced systemic autoimmunity in mice. J. Invest. Dermatol. 126 (2006) 1307-1315
4. Tacca M.D. Prospects for personalized immunosuppression: pharmacologic tools - review. Transplant. Proc. 36 (2004) 687-689
5. Jain A.B., and Fung J.J. Cyclosporin and tacrolimus in clinical transplantation - a comparative review. Clin. Immunother. 5 (1996) 351-373
6. Tamura S., Tokunaga Y., Ibuki R., Amidon G.L., Sezaki H., and Yamashita S. The site-specific transport and metabolism of tacrolimus in rat small intestine. J. Pharmacol. Exp. Ther. 306 (2003) 310-316
7. Venkataramanan R., Swaminathan A., Prasad T., Jain A., Zuckerman S., Warty V., McMichael J., Lever J., Burckart G., and Starzl T. Clinical pharmacokinetics of tacrolimus. Clin. Pharmacokinet. 29 (1995) 404-430
8. Venkataramanan R., Shaw L.M., Sarkozi L., Mullins R., Pirsch J., MacFarlane G., Scheller D., Ersfeld D., Frick M., Fitzsimmons W.E., Virji M., Jain A., Brayman K.L., and Shaked A. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J. Clin. Pharmacol. 41 (2001) 542-551
9. Kawashima Y. Nanoparticulate systems for improved drug delivery. Adv. Drug Deliv. Rev. 47 (2001) 1-2
10. Grenha A., Seijo B., and Remunan-Lopez C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur. J. Pharm. Sci. 25 (2005) 427-437
11. Taylor K.M.G., and McCallion O.N.M. Ultrasonic nebulisers for pulmonary drug delivery. Int. J. Pharm. 153 (1997) 93-104
12. Martinet Y., Pinkston P., Saltini C., Spurzem J., Muller-Quernheim J., and Crystal R.G. Evaluation of the in vitro and in vivo effects of cyclosporine on the lung T-lymphocyte alveolitis of active pulmonary sarcoidosis. Am. Rev. Respir. Dis. 138 (1988) 1242-1248
13. McConville J.T., Overhoff K.A., Sinswat P., Vaughn J.M., Frei B.L., Burgess D.S., Talbert R.L., Peters J.I., Johnston K.P., and Williams R.O. Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharm. Res. 23 (2006) 901-911
14. Noboru I., Takeshi N., Keitarou M., Tsutomu T., Kenji T., Tsunenori T., Yorihisa S., and Mikiro N. Efficacy and safety of inhaled Tacrolimus in rat lung transplantation. J.. Thorac. Cardiovasc. Surg. 2 (2007) 348-553
15. Bosquillon C., Lombry C., Preat V., and Vanbever R. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J. Control. Release 70 (2001) 329-339
16. Rossi S., Buera M.P., Moreno S., and Chirife J. Stabilization of the restriction enzyme EcoRI dried with trehalose and other selected glass-forming solutes. Biotechnol. Prog. 13 (1997) 609-616
17. Steckel H., Eskandar F., and Witthohn K. The effect of formulation variables on the stability of nebulized aviscumine. Int. J. Pharm. 257 (2003) 181-194
18. Fu J., Fiegel J., Krauland E., and Hanes J. New polymeric carriers for controlled drug delivery following inhalation or injection. Biomaterials 23 (2002) 4425-4433
19. Brambilla G., Ganderton D., Garzia R., Lewis D., Meakin B., and Ventura P. Modulation of aerosol clouds produced by pressurised inhalation aerosols. Int. J. Pharm. 186 (1999) 53-61
20. Keenan R.J., Zeevi A., Iacono A.T., Spichty K.J., Cai J.Z., Yousem S.A., Ohori P., Paradis I.L., Kawai A., and Griffith B.P. Efficacy of inhaled cyclosporine in lung transplant patients with refractory rejection: correlation of intragraft cytokine gene expression with pulmonary function and histologic characteristics. Surgery 118 (1995) 385-392
21. Keenan R.J., Duncan A.J., Yousem S.A., Zenati M., Schaper M., Dowling R.D., Alarie Y., Burckart G.J., and Griffith B.P. Improved immunosuppression with aerosolized cyclosporine in experimental pulmonary transplantation. Transplantation 53 (1992) 20-25
22. Blot F., Tavakoli R., Sellam S., Epardeau B., Faurisson F., Bernard N., Becquemin M.-H., Frachon I., Stern M., Pocidalo J.-J., Carbon C., Bisson A., and Caubarrere I. Nebulized cyclosporine for prevention of acute pulmonary allograft rejection in the rat: pharmacokinetic and histologic study. J. Heart Lung Transplant. 14 (1995) 1162-1172
23. Waldrep J.C., Arppe J., Jansa K.A., and Vidgren M. Experimental pulmonary delivery of cyclosporin A by liposome aerosol. Int. J. Pharm. 160 (1998) 239-249
24. Yu Z.S., Rogers T.L., Hu J.H., Johnston K.P., and Williams III R.O. Preparation and characterization of microparticles containing peptide produced by a novel process: spray freezing into liquid. Eur. J. Pharm. Sci. 54 (2002) 221-228
25. Rogers T.L., Nelsen A.C., Hu J.H., Brown J.N., Sarkari M., Young T.J., Johnston K.P., and Williams III R.O. A novel particle engineering technology to enhance dissolution of poorly water soluble drugs: spray-freezing into liquid. Eur. J. Pharm. Sci. 54 (2002) 271-280
26. Rogers T.L., Johnston K.P., and Williams III R.O. Solution-based particle formation of pharmaceutical powders by supercritical or compressed fluid CO2 and cryogenic spray-freezing technologies. Drug Dev. Ind. Pharm. 27 (2001) 1003-1015
27. Rogers T.L., Nelsen A.C., Sarkari M., Young T.J., Johnston K.P., and Williams III R.O. Enhanced aqueous dissolution of a poorly water soluble drug by novel particle engineering technology: spray-freezing into liquid with atmospheric freeze-drying. Pharm. Res. 20 (2003) 485-493
28. Rogers T.L., Overhoff K.A., Shah P., Santiago P., Yacaman M.J., Johnston K.P., and Williams III R.O. Micronized powders of a poorly water soluble drug produced by a spray-freezing into liquid-emulsion process. Eur. J. Pharm. Sci. 55 (2003) 161-172
29. Hu J.H., Johnston K.P., and Williams III R.O. Stable amorphous danazol nanostructured powders with rapid dissolution rates produced by spray freezing into liquid. Drug Dev. Ind. Pharm. 30 (2004) 695-704
30. Evans J.C., Scherzer B.D., Tocco C.D., Kupperblatt G.B., Becker J.N., Wilson D.L., Saghir S., and Elder E.J. Preparation of nanostructured particles of poorly water soluble drugs via a novel ultrarapid freezing technology. Polymeric Drug Delivery II: Polymeric Matrices and Drug Particle Engineering 924 (2006) 320-328
31. Overhoff K.A., Engstrom J.D., Chen B., Scherzer B.D., Milner T.E., Johnston K.P., and Williams III R.O. Novel ultra-rapid freezing particle engineering process for enhancement of dissolution rates of poorly water-soluble drugs. Eur. J. Pharm. Sci. 65 (2007) 57-67
32. Miller F.J., Mercer R.R., and Crapo J.D. Lower respiratory-tract structure of laboratory-animals and humans - dosimetry implications. Aerosol. Sci. Tech. 18 (1993) 257-271
33. Davies N.M., and Feddah M.R. A novel method for assessing dissolution of aerosol inhaler products. Int. J. Pharm. 255 (2003) 175-187
34. Drooge D.J.V., Hinrichs W.L.J., and Frijlink H.W. Incorporation of lipophilic drugs in sugar glasses by lyophilization using a mixture of water and tertiary butyl alcohol as solvent. J. Pharm. Sci. 93 (2004) 713-725
35. Eriksson J.H.C., Hinrichs W.L.J., de Jong G.J., Somsen G.W., and Frijlink H.W. Investigations into the stabilization of drugs by sugar glasses: III. The influence of various high-pH buffers. Pharm. Res. 20 (2003) 1437-1443
36. Wierik H., and Diepenmaat P. Formulation of lactose for inhaled delivery systems. Pharm. Tech. Eur. 11 (2002) 1-5
37. de Boer A.H., Gjaltema D., Hagedoorn P., and Frijlink H.W. Characterization of inhalation aerosols: a critical evaluation of cascade impactor analysis and laser diffraction technique. Int. J. Pharm. 249 (2002) 219-231
38. Zeng X.M., Martin G.P., and Marriott C. The controlled delivery of drugs to the lung. Int. J. Pharm. 124 (1995) 149-164
39. Gao P., Guyton M.E., Huang T.H., Bauer J.M., Stefanski K.J., and Lu Q. Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations. Drug Dev. Ind. Pharm. 30 (2004) 221-229
40. Iervolino M., Cappello B., Raghavan S.L., and Hadgraft J. Penetration enhancement of ibuprofen from supersaturated solutions through human skin. Int. J. Pharm. 212 (2001) 131-141
41. Yamashita K., Nakate T., Okimoto K., Ohike A., Tokunaga Y., Ibuki R., Higaki K., and Kimura T. Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int. J. Pharm. 267 (2003) 79-91